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Abstract: Over the past two decades, the central role of the endothelium in the initiation, 
progression, and clinical sequelae of atherosclerosis has been increasingly recognized. Assess-
ment of the pathobiology of the endothelium and its ability to act as a potential therapeutic 
target remains an area of active research interest. Whilst endothelial function has been shown 
to be a marker for risk of cardiovascular events in high-risk groups, there remains considerable 
debate about the most appropriate way to assess this. We discuss the different clinical methods 
to assess endothelial function, focusing on ﬂ  ow-mediated dilatation (FMD) of the brachial 
artery, highlighting the importance of using a standardized methodology, as well as discussing 
the clinical limitations of using FMD in individuals.
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Physiology of the endothelium
The single layer of endothelial cells lining the blood vessels produces autoimmune, 
endocrine, and paracrine factors (Schechter and Gladwin 2003). Endothelial cells are 
involved in the modulation of platelet activation, leukocyte adhesion, thrombosis, and 
the regulation of vasomotor tone by production of vasoactive substances, particularly 
nitric oxide (NO), endothelin, prostacyclin, and angiotensinogen (Furchgott and 
Zawadzki 1980; Smiesko et al 1985; Pohl et al 1986). By producing nitric oxide, the 
endothelium has a central homeostatic role in the vascular system, allowing organ 
perfusion to be matched to the cardiac output (Rubanyi et al 1986; Corson et al 1996). 
The homeostatic, vasodilator function of the endothelium (mediated by NO) has become 
a useful target for the indirect assessment of NO bioavailability.
Nitric oxide is a key antiatherogenic molecule produced by the healthy 
endothelium (Cooke and Dzau 1997; Kharbanda and Deanﬁ  eld 2001), however 
its protective effects are lost if the endothelium is damaged (Forstermann and 
Munzel 2006).
Atherosclerosis
Atherosclerosis is a systemic arterial disease whereby areas of damaged endothe-
lium promote entry of circulating inﬂ  ammatory cells and set up a process of lipid 
deposition and ﬁ  brosis. Over a number of years the lesions can progress to cause 
luminal narrowing, which can reduce blood ﬂ  ow, or can form a nidus for thrombus 
formation and manifest as acute cardiovascular syndromes such as myocardial 
infarction or stroke.
Conventional risk factors for atherosclerosis can be increasingly identiﬁ  ed in the 
general population but targeting those likely to develop disease and maximizing the 
beneﬁ  ts of any intervention has not been realized. Risk factors associated with the 
development of atherosclerosis include age, smoking, hypertension, diabetes and family 
history, but despite large scale epidemiological studies, approximately half the burden Vascular Health and Risk Management 2008:4(3) 648
Al-Qaisi et al
of atherosclerotic cardiovascular disease is unexplained by 
conventional risk factors. Patients with manifest complica-
tions of atherosclerosis and those who are at high risk of 
future cardiovascular events require aggressive treatment 
of risk factors. Risk factor modiﬁ  cation is associated with 
improved outcome (Ford et al 2007).
Disturbances in vascular biology provide a pathophysi-
ological basis to identify individuals at future increased 
risk of acute cardiovascular events (Celermajer et al 1994; 
Halcox et al 2002; Shimbo et al 2007). Anatomical assess-
ment of coronary atherosclerosis by intravascular ultrasound 
or assessment of carotid intima media thickness are currently 
accepted as suitable surrogate clinical trial endpoints by the 
Food and Drug Administration in the United States for cardio-
vascular intervention trials (Sankatsing et al 2005; Nicholls 
et al 2006). Some studies have suggested a link between 
improved vascular function and outcome (Suessenbacher 
et al 2006), however this remains to be conﬁ  rmed in larger 
studies, and the question of whether targeted improvement 
of endothelial function translates into clinical beneﬁ  t has 
not been answered.
Primary prevention is an altogether more controversial 
area. Atherosclerosis takes many decades to develop and 
can be considered a disease of childhood (Leeson et al 1997; 
Reilly et al 2005). Prevention of early atherosclerosis at its 
preclinical stage would have major global health impact. 
However work is still emerging on the approach to its 
identiﬁ  cation and treatment in the young (Celermajer and 
Ayer 2006).
Measures of endothelial function
There are many techniques for assessing endothelial func-
tion. These techniques can be either invasive or noninvasive, 
and assess different aspects of pathobiology (1). For the 
assessment of pre-clinical disease, the ideal technique for 
measuring endothelial function must be noninvasive, reli-
able, reproducible, cheap, and easy to perform (Deanﬁ  eld 
et al 2007).
Invasive techniques
Vasoactive agents are delivered via intra-arterial infu-
sion, whilst the response is measured with high resolu-
tion ultrasound or strain gauge plethysmography. In 
addition, intravascular infusions of vasoactive stimulants 
can be combined with intravascular ultrasound. For example, 
intravascular coronary flow-mediated dilatation (FMD) 
studies (Halcox et al 2002) or studies of radial artery grafts 
used for coronary bypass surgery (Chong et al 2006).
Noninvasive techniques
Noninvasive methods of measuring endothelial function 
include ultrasound FMD, salbutamol-mediated endothelial 
function measured by pulse wave analysis (PWA) or pulse 
contour analysis (PCA), ﬂ  ow-mediated magnetic resonance 
imaging (MRI), laser Doppler ﬂ  owmetry, and ﬂ  ow-mediated 
pulse amplitude tonometry (PAT).
Noninvasive ultrasound FMD of the brachial artery is the 
most widely used method for both small and large population 
studies of adults and children. FMD measured by MRI has 
been validated against ultrasound for measuring endothelial 
function. Although it is less operator-dependent than ultra-
sound, and allows simultaneous assessment of peripheral and 
central endothelial function, it is more expensive, less widely 
available, and has the general disadvantages of MR-based 
techniques (Leeson et al 2006).
Pulse wave analysis and PCA with salbutamol are more 
recent methods which may be cheaper than ultrasound FMD 
but require larger sample sizes as there is more variability; in 
addition they have been shown to be less reliable in children 
(Donald et al 2006).
Microvascular techniques
Laser Doppler skin ﬂ  owmetry has been correlated with endo-
thelial function of the brachial artery (Hansell et al 2004). It 
has been used as a research tool (Strain et al 2005), however 
it remains uncertain if this technique reﬂ  ects the same patho-
biology as that of conduit vessel endothelial dysfunction.
Digital PAT is also a recent technology which has 
been shown to correlate with microvascular endothelial 
dysfunction of the coronary arteries (Bonetti et al 2004). 
More data is required on its reproducibility and its utility for 
assessment of endothelial function.
Table 1 Methods for measuring endothelial function
Technique Method
Invasive Intra-arterial ACh or edothelin infusion and strain 
gauge plethysmography (or high resolution ultrasound)
Intravascular US studies of epicardial coronary arteries
Noninvasive US FMD of the brachial artery
Flow-mediated MRI
Pulse wave analysis (PWA) applanation tonometry 
with inhaled salbutamol (B2 agonist for global 
endothelial NO release)
Pulse contour analysis (PCA) digital 
photoplethysmography with inhaled salbutamol
(B2 agonist for global endothelial NO release)
Microvascular Laser Doppler skin ﬂ  owmetry
Digital pulse amplitude tonometry (PAT)  
Abbreviations: FMD, ﬂ  ow-mediated dilation; MRI, magnetic resonance imaging; NO, 
nitric oxide; US, United States of America.Vascular Health and Risk Management 2008:4(3) 649
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Flow-mediated dilatation
of the brachial artery
Noninvasive brachial artery assessment of FMD has 
emerged as an important research tool for assessment of 
endothelial function. Measuring endothelial function in the 
brachial artery may offer a noninvasive measure of pre-
clinical cardiovascular risk in populations with and with-
out obvious risk factors (Celermajer et al 1994; Anderson 
2007), although the results of larger outcome studies are 
still emerging (Shimbo et al 2007; Yeboah et al 2007). 
Preclinical detection of endothelial dysfunction will enable 
interventions to be targeted and monitored at an early stage 
in the disease process.
Brachial artery FMD has been utilized for measurement 
of endothelial function for over 15 years (Anderson and 
Mark 1989; Celermajer et al 1992). FMD is the measure-
ment of transient changes in brachial artery diameter in 
response to shear stress. An increase in ﬂ  ow in the brachial 
artery is achieved by inﬂ  ation of a pneumatic cuff (placed 
on the forearm, distal to the ultrasound imaging site) to 
suprasystolic pressure for 5 minutes (see Figure 1). On 
deﬂ  ation of the cuff, the increased ﬂ  ow results in shear 
stress which activates endothelial nitric oxide synthase to 
release NO via the L-arginine pathway. The NO diffuses 
to the smooth muscle cells causing them to relax result-
ing in vasodilatation. FMD is measured as the percentage 
change in brachial artery diameter from baseline in response 
to the increased ﬂ  ow. Noninvasive ultrasound FMD of 
the brachial artery is now widely quoted in the literature, 
however, standardization of its methodology must precede 
its clinical application.
Towards a standard methodology 
for ultrasound FMD of the brachial 
artery
Despite being the most frequently used technique, a closer 
look at the literature reveals that there are wide variations 
in mean FMD between studies of the same populations 
Figure 1 Probe position in relation to cuff.Vascular Health and Risk Management 2008:4(3) 650
Al-Qaisi et al
(Bots et al 2005). At present the lack of a scientiﬁ  c consensus 
on a standard protocol for measuring FMD precludes the 
accurate comparison of data between centers.
Guidelines for assessment of endothelial function in 
the brachial artery were published by an international task 
force (Corretti et al 2002); however these failed to come to 
an agreement as to the fundamental position of the cuff in 
relation to the ultrasound probe. This is recognized as the 
major difference between sites and produces discrepancies 
in FMD measurements in similar populations. In the 
interim, the working group on Endothelin and Endothelial 
Factors of the European Society of Hypertension (Deanﬁ  eld 
et al 2005) have written a comprehensive update on 
endothelial function techniques. In addition, Donald and 
colleagues (2006) provide an explicit methodology for 
ultrasound FMD.
Standardization of FMD 
methodology
There are four critical elements of FMD methodology that 
need to be standardized:
•  Probe position in relation to cuff.
•  Shear stimulus (cuff occlusion time).
•  Image measurement (stereotaxis and automation).
•  Control of environmental factors.
Probe position in relation to cuff
The original method for brachial FMD described the cuff 
distal to the probe (Anderson and Mark 1989; Celermajer 
et al 1992), the cuff was placed around the forearm, and 
the brachial artery was imaged above the ante-cubital 
fossa.
Later, a second method developed with the cuff placed 
proximal to the imaging site. If the cuff is placed proximal 
to the transducer, the dilatation measured is greater, and, 
when this is the case, it is not clear what aspect of endothe-
lial function is being measured (Berry et al 2000; Agewall 
et al 2001; Peretz et al 2007; Guthikonda et al 2007). NO-
dependent FMD measurement becomes confounded by 
super-added ischemic (NO-independent) vasodilatation 
(Doshi et al 2001).
Therefore, if the aim of the study is to assess NO bio-
availability, the cuff should be distal in position to the probe 
(see Figure 1).
Shear stimulus (cuff occlusion time)
Varying lengths of cuff occlusion time have been used, 
but there is a general consensus that 5 minutes is the 
optimum time to elicit a good reactive hyperemia response 
and consequent dilatation. Studies have shown that the 
dilatatory response after prolonged cuff occlusion times 
(eg, 15 minutes) is not a pure NO-mediated event (Mullen 
et al 2001).
Image measurement (stereotaxis
and automation)
With the introduction of electronic measurement for diameter 
change, it is imperative to have high-quality static images, 
which can only be acquired using micrometer-adjustable 
stereotactic apparatus (see Figure 4A in Deanﬁ  eld et al 
2007). Each image should be measured at end diastole, and 
the maximal dilation should be recorded rather than the 
dilation at any set time post cuff release; it has been shown 
that taking a measurement at a set time of 60 seconds, for 
example, misses the peak dilatation in approximately 70% 
of subjects (Palinkas et al 2002). Using this type of equip-
ment and protocol can minimize inter-observer variability 
to within a range that is feasible for clinical application 
(Herrington et al 2001).
Control of environmental factors
Control of environmental factors is important for the longi-
tudinal consistency of FMD measurements. The pertinent 
factors which are known to affect FMD measurements 
include room temperature, time of day, ingestion of fatty 
foods or caffeine, concurrent inﬂ  ammation or infection, and 
stage of menstrual cycle (Hashimoto et al 1995; Leeson et al 
1997; Williams et al 1999; Hingorani et al 2000; Duffey et al 
2001; Charakida et al 2005).
Is there any clinical value
in measuring FMD?
When performed by experienced personnel in a standardised 
setting with a rigid protocol, brachial artery FMD is a useful 
measure of NO-dependent endothelial function. If applied 
rigorously, FMD may serve as a marker for cardiac risk 
factors exposure and their functional biological effects 
in healthy volunteers (Celermajer et al 1994). However, 
screening for risk factors exposure is complicated by the 
fact that there is a wide variation in atheroscelorotic burden 
for similar risk factor exposure, and a considerable lag time 
between exposure to a risk factor and the manifestation of 
cardiovascular disease.
As a marker for preclinical disease, it has been sug-
gested that FMD may be more closely correlated with the 
non-Framingham (ie, low or medium) risk factors than Vascular Health and Risk Management 2008:4(3) 651
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Framingham (high-level) risk factors (Witte et al 2005), 
however, in higher risk populations FMD has been investi-
gated as a risk assessment tool and in patients having surgery 
for PVD, it is an independent predictor of cardiovascular 
events (Gokce et al 2003). In a recent study, Matsushima 
and colleagues (2007) claim that brachial artery FMD can 
diagnose the presence of coronary stenosis in high-risk 
individuals with similar accuracy to treadmill testing. Also, 
in small scale clinical studies, FMD has been found to be an 
independent predictor for further cardiac events in patients 
post myocardial infarction (Anderson et al 1995; Karatzis 
et al 2006).
Despite this clinical data, the acute, dynamic nature of the 
endothelium and its response to environmental factors gives 
rise to confounding results for a single FMD examination. If 
the environmental factors which are known to affect acutely 
endothelial function are not accounted for during testing, it is 
possible to get a false positive result for endothelial dysfunc-
tion, ie, a low FMD which may only be a transient state and 
not representative of pathology. As yet there is no standard 
protocol for the clinical application of FMD, and because 
single measurements can be so misleading, any clinical 
application would need to conﬁ  rm endothelial dysfunction 
with repeat studies.
Presently, FMD remains a valuable and important 
research tool for studying populations rather than indi-
viduals. The additive value of brachial ultrasound FMD 
over and above established traditional clinical tools as 
yet remains to be proven, and ongoing studies continue to 
address this issue.
Conclusion
Validation of FMD continues in controlled research contexts. 
It is rapid and cheap. To date its reproducibility (and accuracy) 
as a tool to help in the management of asymptomatic and 
symptomatic individuals is unproven. Brachial ultrasound 
FMD allows the early detection of patients who would not 
be eligible for medical therapy under current guidelines, but 
who are at increased risk for cardiovascular events. There 
is no doubt that a test which detects otherwise (silent) car-
diovascular risk would allow early intervention by lifestyle 
change, or drug therapy, and primary prevention could start 
as early as childhood (Celermajer and Ayer 2006). This in 
the long-term could dramatically reduce the mushrooming 
burden of cardiovascular disease on the healthcare system. 
However as FMD is technically demanding, implementation 
into a clinical setting would require standardized protocols 
and funding for recognized training within an established 
training pathway such as echocardiography or vascular 
technology.
It remains to be seen if the theoretical potential of ultra-
sound FMD as a research tool can ever be matched by its 
application in the less forgiving clinical environment.
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